Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases (NAREG)

Santé Arménie French-Armenian Research Center

Status: Enrolling

Conditions: Giant Cell Arteritis; Celiac Disease; Sjogren's Syndrome; Behcet Disease; Hereditary and Acquired Angioedema; Takayasu Arteritis; Primary Antiphospholipid Syndrome; Antineutrophil Cytoplasmic Antibody (ANCA) Positive Vasculitis; Rheumatoid Arthritis

Treatments: Other: Usual medical management of patients, additional blood and stool samples for biobanking

Study type: Observational

Funder types: Other

Identifiers

NCT05904301

SA-2021001

Details and patient eligibility

About

Longitudinal prospective multicenter Armenian registry of systemic autoimmune, autoinflammatory diseases with constitution of bio-banking.

Full description

Autoimmune and auto inflammatory diseases are a growing group of disorders caused by a dysregulation of the innate immune system leading to episodes of systemic inflammation.

They represent a group of diseases characterized by excessive autoimmune or inflammatory reaction leading to various organ damage and drop in patient's quality of life, usually underlined by particular genetic factors and environmental triggers.

The progress of these diseases is often evaluated in the form of activity scores.

A number of scores are available to predict the evolution of autoimmune autoinflammatory diseases.

For a long time, these pathologies have remained slightly explored because of their complex physiopathology and the absence of specific therapies.

In the last few years, significant progress has been made in terms of both pathophysiology and treatment.

Treatment with biological targeted therapies transformed the prognosis and survival of the patients, improved their quality of life and underlined the necessity of a global management of these patients.

In Armenia, the epidemiological elements of these pathologies are not known, nor are the circumstances of their discovery. The initial biological manifestations and the management of these patients are variable from one center to another, whether in terms of supportive or specific therapeutic elements.

Enrollment: 800 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients with a confirmed diagnosis of at least one of following autoimmune systemic diseases:

   Behcet disease, ANCA -positive vasculitis, Takayasu arteritis, Giant cell arteritis, Systemic sclerosis, Sjogren syndrome, Rheumatoid arthritis, Spondylarthritis (psoriatic, ankylosing, crohn's related), Angioedema hereditary and acquired, Pediatric dermatology, Autoinflammatory diseases (hereditary and acquired), Unexplained infertility, Immune thrombocytopenic purpura/ Autoimmune hemolytic anemia (ITP, AHA), Primary anti-phospholipid syndrome (APS), Celiac disease.

2. Age: major and minor

3. Patients who have been informed and provided with written informed consent to participate Or consent from legal representative

Exclusion criteria

1. Patients refusing to participate in the registry
2. Non-consent from legal representative
3. Breastfeeding or pregnant patients

Trial design

800 participants in 1 patient group

Systemic autoimmune and autoinflammatory diseases

Treatment:

Other: Usual medical management of patients, additional blood and stool samples for biobanking